

Antimicrobial Resistance: A One Health Approach to Addressing Global Health and Food Security Challenges

Mahendra Pal^{1*} and Tesfaye Rebuma²

¹Narayan Consultancy on Veterinary Public Health and Microbiology, Bharuch, Gujarat, India.

²Shaggar City administration Sebeta Sub city Agricultural office, Sebeta, Oromia, Ethiopia

***Corresponding author:** Pal M, Narayan Consultancy on Veterinary Public Health and Microbiology, Bharuch Gujarat, India; E-mail: [palmahendra2\[AT\]gmail.com](mailto:palmahendra2@gmail.com)

Received: July 06, 2025; **Accepted:** December 23, 2025; **Published:** January 27, 2026



All articles published by Gnoscience are Open Access under the Creative Commons Attribution License BY-NC-SA.

Abstract

Antimicrobial resistance (AMR) is a growing global health threat that jeopardizes both human and animal health, with significant economic implications. The overuse and misuse of antibiotics in human medicine, agriculture, and veterinary practices have driven the development of resistance, making infections harder to treat and increasing the risk of disease spread. In particular, the use of antibiotics in livestock and aquaculture has accelerated the emergence of resistant pathogens that can transfer to humans via the food chain. AMR is linked to an increase in morbidity and mortality rates, extended hospital stays, and higher healthcare costs. Projections suggest that AMR could lead to up to 10 million deaths annually by 2050, with devastating impacts on global economies, particularly in low- and middle-income countries. Addressing AMR requires a multi-faceted approach, including stricter antibiotic regulations, improved management practices in agriculture, and enhanced surveillance systems. This article reviews the mechanisms of AMR, its global and regional implications, and the strategies needed to mitigate its impact on public health and food security.

Keywords: Antimicrobial resistance; Antibiotics, Economic impact; Food security; Global health; Public health.

1. Introduction

Antibiotics, naturally derived, synthetic, or semi-synthetic, inhibit or eliminate microorganism growth. Their extensive use in dairy, cattle, poultry, aquaculture, and beekeeping industries worldwide has contributed to their widespread availability and affordability. However, bacteria are increasingly acquiring resistance to diverse antibiotics, driven by horizontal gene transfer from resistant bacteria or through new genetic mutations, intensifying the global AMR challenge [1].

One of the biggest threats to global health is antimicrobial resistance (AMR), which presents significant public health and economic challenges. In 2019, AMR was associated with approximately 1.27 million deaths worldwide. The primary

Citation: Pal M and Rebuma T. Antimicrobial resistance: A one health approach to addressing global health and food security challenges. J Bio Med Open Access. 2026;6(1):135.

drivers of AMR are the overuse and misuse of antimicrobials across human, animal, and plant sectors [2]. AMR adversely affects both human and veterinary medicine, threatening public health and food security. As global livestock production expands, the reliance on antibiotics intensifies. However, improper or excessive antibiotic use contributes to the emergence of antibiotic-resistant bacteria, which can contaminate food and exacerbate the AMR crisis [3].

Over the past 40 years, research has identified key drivers of antimicrobial resistance (AMR) in East Africa, including excessive antibiotic use in small-scale production systems, close human-animal interactions, lack of withdrawal periods before consuming animal-derived products, and poor antibiotic use management (AMU). These practices have exacerbated AMR, rendering previously effective treatments for infectious diseases inadequate. In Ethiopia, high antibiotic use spans public health and veterinary sectors, with limited government oversight of the pharmaceutical industry and inadequate guidance on safe veterinary medication use. Additionally, food products can act as reservoirs and vectors for antibiotic-resistant bacteria, facilitating the efficient transfer of AMR factors to human digestive systems [4].

Antimicrobial resistance (AMR) in animal products arises when edible parts retain residues of veterinary medications, including parent compounds, metabolites, and contaminants. Consuming these products at levels exceeding standard residual limits can have serious health consequences. Veterinary medication residues, comprising pharmacologically active substances and their breakdown products, are frequently detected in animal-derived foods such as milk and meat [5].

Cattle and their products can serve as reservoirs for AMR bacteria, facilitating the transfer of resistant pathogens to humans through the food chain [6]. Notable antibiotic-resistant pathogens, including *Salmonella*, *Staphylococcus aureus*, and *Escherichia coli*, have emerged as significant challenges to global healthcare [7], [8]. In Ethiopia, studies in the veterinary and public health sectors have revealed a fragmented prevalence and susceptibility profile for these pathogens, highlighting gaps in AMR management [9]. Therefore, the objective of this article is to review the mechanisms of AMR, its global and regional implications, and the strategies needed to mitigate its impact on public health and food security.

2. Literature Review on AMR

2.1 Definition and History of Antimicrobial Resistance

Antimicrobial resistance (AMR) poses a severe global health threat, undermining the effectiveness of antibiotics, antivirals, antifungals, and antiparasitic. AMR occurs when microorganisms including bacteria, viruses, fungi, and parasites develop resistance to previously effective treatments, leading to increased morbidity, mortality, and healthcare costs [10]. The growing prevalence of AMR has escalated global concern, emphasizing the need for coordinated action across governments, healthcare providers, researchers, and the public [11]. Addressing AMR is now a critical health priority to safeguard the well-being of populations worldwide [12].

The history of antimicrobial resistance (AMR) dates back to the discovery of penicillin by Fleming in 1929 and its widespread use in the 1940s [13]. Resistance emerged quickly, with penicillin-resistant *Staphylococcus aureus* reported

in 1942 and tetracycline resistance by 1953 [14], [15]. The agricultural use of antibiotics in the 1950s–1960s further accelerated resistance, and methicillin-resistant *Staphylococcus aureus* (MRSA) was identified in 1961 [16]. By the 1980s, multidrug-resistant (MDR) tuberculosis had become a global epidemic, and in the 1990s, *Escherichia coli* and *Klebsiella pneumoniae* developed resistance to extended-spectrum beta-lactamases (ESBL) [17], [18].

The escalation of MDR bacteria has significantly reduced the efficacy of antibiotics, leading to a decline in antibiotic development by pharmaceutical companies. Today, healthcare systems face a "post-antibiotic era" where common infections and minor injuries risk becoming fatal. Without urgent solutions, AMR is projected to cause millions of deaths annually, posing a dire global health challenge.

2.2 Mechanisms of Antimicrobial Resistance

Antimicrobial resistance (AMR) arises when microorganisms develop the ability to survive exposure to antimicrobial agents designed to eliminate them or inhibit their growth [19]. Microorganisms achieve resistance through various mechanisms, including genetic mutations, horizontal gene transfer, and alteration of drug targets, drug inactivation, efflux pumps, and biofilm formation. Genetic mutations, and changes in the DNA sequence, play a pivotal role in AMR development. These mutations may occur spontaneously or be induced by the presence of antimicrobial agents, enabling microorganisms to evade drug effects [20].

Microorganisms develop AMR through genetic transfer mechanisms like horizontal gene transfer, which facilitates the sharing of resistance genes between organisms, often via plasmids or transposons [21], [22]. Resistance can also arise from alterations to drug targets, rendering antimicrobials less effective [21], [23]. Additionally, bacteria may produce enzymes that neutralize antimicrobial agents or use efflux pumps to expel drugs, preventing their accumulation to effective concentrations [24], [25].

Certain microorganisms can form biofilms, which are thin layers of microbial communities attached to surfaces and encased in an extracellular matrix. These biofilms provide a protective barrier against antimicrobial agents, making it significantly more challenging to eliminate the microorganisms within them [26].

2.3 Emergence of Antimicrobial Resistance

The history of antimicrobial resistance (AMR) reveals its deep-rooted origins. AMR was first described in *Escherichia coli* (then *Bacillus coli*) in 1940, shortly before penicillin was widely used in human medicine and after its discovery by Fleming in 1929 [27]. Since many medical antimicrobials are naturally derived from soil microorganisms, it has been known for over 40 years that these microorganisms harbor resistance genes that are now found in clinically significant bacteria [28]. Phylogenetic studies suggest that AMR genes existed long before antibiotic use, but retrospective analyses indicate that resistance was rare in clinical isolates before antibiotic introduction [29], [30].

2.4 Antimicrobial Use and Resistance Development

The primary driver of antimicrobial resistance (AMR) is the widespread use of antimicrobial medications across various sectors. These medications are used in veterinary clinics, farms, and feedlots, as well as in hospitals, outpatient facilities, and long-term care settings. In agriculture, antimicrobials are commonly administered to animals raised for food to

treat or prevent disease, with some being added to nearly all animal feed at sub-therapeutic concentrations to promote growth and prevent illness. Food processing facilities also use antimicrobial agents to control bacterial growth and ensure the safety and quality of the final products [31].

Despite extensive research and scientific evidence supporting the link between antimicrobial use in agriculture and the development of antimicrobial resistance (AMR) in human diseases, some skeptics still question this connection. Globally, the amount of antibiotics used in food animals is believed to exceed that used in humans, with nearly every class of antibiotics utilized in both human medicine and food production. Overuse and misuse of antibiotics are recognized as major contributors to AMR, as these practices create selection pressure on both environmental bacteria and the microbiota of humans and animals [32].

Antibiotics can also activate gene expression, promoting mutations or the development of resistance genes in bacteria [33]. Through gene transfer, resistance genes can spread from agricultural bacteria to human pathogens. The potential for resistant pathogens to spread from one individual to others poses a significant global public health threat. Additionally, antibiotic residues in animal feed and waste can contaminate soil and water, impacting environmental and aquatic microbiomes [34]. Given that a large percentage (75–90%) of antibiotics administered to cattle are excreted unmetabolized, the persistence of these residues further elevates the risk of AMR development [31].

2.5 Mechanisms of Spread of Antimicrobial Resistance between Animals and Humans

Humans can be exposed to antimicrobial-resistant bacteria through direct contact with animals or their waste, as well as through the consumption of food contaminated with resistant bacteria (Fig. 1) [31]. Additionally, fomites, or inanimate objects, can play a significant role in the local and global transmission of these resistant bacteria. Genetic exchange between different strains or species can occur, enabling the spread of resistance genes. This genetic transfer can take place in environments where susceptible bacteria come into contact with resistant ones, such as the human or animal gut, agricultural soil treated with slurry, or aquatic ecosystems [35].

Resistance genes can travel from humans to poultry farms, raising concerns about contamination in water, food crops, and animal feed due to environmental bacteria acquiring resistance. This contamination can promote the exchange of resistance traits with commensal or pathogenic species in the gut microbiota of both animals and humans, posing substantial health risks [36]. However, there is limited information on the role of this transmission route in the spread of AMR. The environmental fate of different antimicrobials can vary, and it is crucial to consider that residues from pharmaceutical production or human antimicrobial treatments may also contribute to the selection of resistant bacteria in the environment [29].




Fig. 1. Spread of antimicrobial resistance between animals and humans [37].

2.6 The impact of AMR on Human and Animal Populations

Antimicrobial resistance (AMR) has become one of the most critical health challenges of the 21st century. Infections once easily treatable are increasingly difficult to manage, leading to significant clinical and public health concerns. The loss of effective first-line antimicrobials has necessitated the use of second and third-line therapies, which are often costlier and more toxic and require longer treatment durations. Prolonged illnesses increase the burden on healthcare systems through extended hospital stays, additional outpatient visits, laboratory testing, and the need for isolation measures. They also strain individual and societal resources, reducing economic productivity due to longer recovery times and missed work [38].

Over a million people die every year from AMR infections [39]. Without effective antibiotics, routine medical procedures like surgeries, organ transplants, chemotherapy, and neonatal care could become much more dangerous because of infections that aren't under control [40]. Bacteria like *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species are some of the most dangerous AMR threats in healthcare settings [41].

AMR threatens human health and food production by enabling animal-to-human transfer of resistant zoonotic pathogens [42]. Overuse of antibiotics in livestock to treat illness and promote livestock growth has precipitated reservoirs of resistance. This facilitates enhanced transmission risks of MDR bacteria like *Salmonella* and *Campylobacter* via the food chain or animal handlers [43]. Resistant bacterial strains spread readily between species. Wildlife similarly develops AMR from indirect environmental exposures driving additional pathogen transmission. Resistant microbes extend into the broader environment through fertilizers made from manure, contaminating waterways and produce that reaches consumer tables. They additionally exchange AMR genes with normal environmental and human commensal microflora. Restricted treatment options for animal infections resulting from resistance promote outbreak escalation among cattle, poultry, and sheep, necessitating culling and generating significant economic losses while threatening food supplies. Approximations indicate AMR could impose a \$3–4 billion financial burden through livestock alone in the coming decades [44].

Detrimental resistance impacts across agriculture and economic systems also spur disruptive ripple effects for national security and trade. Hence, a proper One Health approach encompassing human, animal, and environmental health surveillance and interventions remains necessary to fully address AMR's substantial existing and prospective adverse impacts on animals that, in turn, heighten human exposure risks further [45].

2.7 Impact on the Global Economy

Antimicrobial resistance (AMR) disproportionately impacts certain populations and regions, with low- and middle-income countries and vulnerable groups enduring the greatest burden. According to the World Health Organization (WHO), over 75% of the global population is affected by AMR, particularly individuals living with HIV, those with chronic illnesses, and patients in healthcare settings where infection risks are elevated [46]. Currently, antibiotic-resistant infections cause over 700,000 deaths annually, and this figure could rise to 10 million deaths per year by 2050 if current trends persist. These alarming projections highlight the critical need for coordinated global action to address AMR effectively [47].

AMR poses a considerable challenge in effectively combating numerous infectious diseases, rendering their treatment increasingly arduous [48]. Certain significant global phenomena in AMR encompass the rise of antibiotic-resistant bacteria, exemplified by methicillin-resistant *Staphylococcus aureus* (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE). The dissemination of multidrug-resistant tuberculosis (MDR-TB) represents another prevailing occurrence. AMR instills mounting apprehension within the context of sexually transmitted infections, notably gonorrhea. Additionally, it progressively compromises the efficacy of novel antimicrobial agents, including antivirals and antifungals [49]. Countries must collaborate on a global scale to combat this predicament effectively, as AMR transcends geographical boundaries and exhibits the potential for seamless cross-border propagation [50].

2.8 Impact of Antibiotic Resistance

Antibiotic resistance (ABR) poses significant threats to public health, global economies, and food security. Treatable infections become harder to manage, resulting in prolonged illnesses, complications, and over 700,000 deaths annually. This figure is projected to rise to 10 million deaths per year by 2050 if current trends continue [47]. Resistance necessitates the use of expensive and often toxic second- or third-line treatments, leading to prolonged hospital stays and increased healthcare costs [38]. Antibiotic resistance affects workforce productivity and incurs significant costs related to healthcare and food production, with an estimated burden of \$3–4 billion in livestock sectors alone in the coming decades [44]. Routine medical procedures like surgeries, organ transplants, and cancer therapies become riskier due to the limited efficacy of antibiotics to prevent and treat infections [40]. Resistance in agricultural settings leads to animal disease outbreaks, reduced production, and compromised food safety due to contaminated produce and water sources [43].

3. Conclusion and Recommendations

Antimicrobial resistance (AMR) represents one of the most pressing global health crises of the 21st century. The overuse and misuse of antibiotics in human medicine, agriculture, and veterinary practices have accelerated the development and spread of AMR, undermining the efficacy of life-saving drugs. Genetic mutations, horizontal gene transfer, and

biofilm formation enable microorganisms to evade treatment, increasing morbidity, mortality, and economic burdens. AMR poses significant threats to public health, food security, and global economies, especially in low- and middle-income countries. Without immediate and coordinated action, the spread of AMR could result in catastrophic outcomes, including millions of preventable deaths annually, escalating healthcare costs, and reduced agricultural productivity.

Based on the above conclusion, the following recommendations were forwarded:

- Strengthened cross-sectoral collaboration can improve surveillance, prevention, and management of AMR.
- Agriculture should restrict antibiotics to therapeutic use, prohibiting sub-therapeutic and growth-promoting use.
- Robust national and international surveillance systems should monitor antibiotic usage and resistance patterns in humans, animals, and the environment.
- Education of healthcare providers and farmers, and the public on the risks of antibiotic misuse and AMR is crucial.
- Investment in new antimicrobials and alternatives therapies (e.g., phage therapy), and vaccines is critical.
- Strengthening infection prevention and control measures in healthcare facilities, farms, and food production systems can reduce the spread of resistant pathogens.

4. Contribution of Authors

Both authors contributed equally during the preparation of the manuscript.

5. Conflict of Authors

The authors declare no conflict of interest.

6. Source of Funding

This study received no external funding.

REFERENCES

1. Cox G, Wright GD. Intrinsic antibiotic resistance: mechanisms, origins, challenges and solutions. *Int J Med Microbiol.* 2013;303(6-7):287-292.
2. Pal M, Regassa M, Rabuma T, et al. Antimicrobial resistance: Navigating an unfolding public health crisis. *Am J Med Biol Res.* 2024;12(1):27-35.
3. Phu VD, Wertheim HF, Larsson M, et al. Burden of hospital acquired infections and antimicrobial use in Vietnamese adult intensive care units. *PloS One.* 2016;11(1):e0147544.
4. Spanu V, Spanu C, Virdis S, et al. Virulence factors and genetic variability of *Staphylococcus aureus* strains isolated from raw sheep's milk cheese. *Int J Food Microbiol.* 2012;53(1-2):53-57.
5. Abdeta TR and Hunde MR. Review on the antimicrobial resistance and its effects on public health. *Int J Med Parasitol Epidemiol Sci.* 2024;5(2):57-61.
6. Normanno G, La Salandra G, Dambrosio A, et al. Occurrence, characterization and antimicrobial resistance of enterotoxigenic *Staphylococcus aureus* isolated from meat and dairy products. *Int J Food Microbiol.* 2007;115(3):290-296.

7. Kashef N, Djavid GE, Shahbazi S. Antimicrobial susceptibility patterns of community-acquired uropathogens in Tehran, Iran. *J Infect Dev Ctries*. 2010;4 (04):202-206.
8. Pal M, Rebuma T, Regassa T, et al. Methicillin-Resistant Staphylococcus Aureus (MRSA) Remains a major threat to public health. *Am J Public Health*. 2024;12(3):48-53.
9. Hailu D, Gelaw A, Molla W, et al. Prevalence and antibiotic resistance patterns of Salmonella isolates from lactating cows and in-contact humans in dairy farms, Northwest Ethiopia. *J Environ Occupat Sci*. 2015;4 (4):171-178.
10. Aslam B, Wang W, Arshad MI, et al. Antibiotic resistance: A rundown of a global crisis. *Infect Drug Resist*. 2018; 10:1645-1658.
11. Padiyara P, Inoue H, Sprenger M. Global governance mechanisms to address antimicrobial resistance. *Infect Dis Res Treatment*. 2018;11:1178633718767887.
12. Castañeda-Barba S, Top EM, Stalder T. Plasmids, a molecular cornerstone of antimicrobial resistance in the One Health era. *Nat Rev Microbiol*. 2024;22(1):18-32.
13. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. *British J Experiment Pathol*. 1929;10(3):226–236.
14. Rammelkamp CH and Maxon T. Resistance of Staphylococcus aureus to the action of penicillin. *Proceed Society Experiment Biol Med*. 1942;51(3):386-389.
15. Knight V and Holzer AR. Studies on staphylococci from hospital patients. I. Predominance of strains of group III phage patterns which are resistant to multiple antibiotics. *J Clin Investigat*. 1954;33(9):1190-1198.
16. Parker MT and Jevons MP. A survey of methicillin resistance in Staphylococcus aureus. *Postgraduate Medical J*. 1964;40:170-178.
17. Steiner P, Rao M, Mitchell M, et al. Primary drug-resistant tuberculosis in children: Correlation of drug-susceptibility patterns of matched patient and source case strains of Mycobacterium tuberculosis. *Am J Dis Child*. 1985;139(8):780–782.
18. Jacoby GA and Han P. Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. *J Clin Microbiol*. 1996;34(4):908–911.
19. Centers for Disease Control and Prevention (CDC). How do germs become resistant? [Online]. Available: <https://www.cdc.gov/drugresistance/about/how-resistance-happens.html>. Accessed January 4, 2023.
20. Coculescu BI. Antimicrobial resistance induced by genetic changes. *J Med Life*. 2009;2(2):114–123.
21. Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. *AIMS Microbiol*. 2018;4(3):482–501.
22. Bello-López JM, Cabrero-Martínez OA, Ibáñez-Cervantes G, et al. Horizontal gene transfer and its association with antibiotic resistance in the genus Aeromonas spp. *Microorganisms*. 2019;7(9):363.
23. Martinez JL. General principles of antibiotic resistance in bacteria. *Drug Discov Today Technol*. 2014;11:33–39.
24. Egorov AM, Ulyashova MM, and Rubtsova MY. Bacterial enzymes and antibiotic resistance. *Acta Naturae*. 2018;10(4):33–48.
25. Sun J, Deng Z, and Yan A. Bacterial multidrug efflux pumps: Mechanisms, physiology and pharmacological exploitations. *Biochem Biophys Res Commun*. 2014;453(2):254–267.

26. Sharma D, Misba L, and Khan AU. Antibiotics versus biofilm: An emerging battleground in microbial communities. *Antimicrob Resist Infect Control*. 2019;8:76.
27. Chain E, Florey HW, Gardner AD, et al. Penicillin as a chemotherapeutic agent. *Lancet*. 1940;236(6104):226–228.
28. Benveniste R and Davies J. Aminoglycoside antibiotic-inactivating enzymes in actinomycetes similar to those present in clinical isolates of antibiotic-resistant bacteria. *Proc Natl Acad Sci USA*. 1973;70(8):2276–2280.
29. Wellington EM, Boxall AB, Cross P, et al. The role of the natural environment in the emergence of antibiotic resistance in Gram-negative bacteria. *Lancet Infect Dis*. 2013;13(2):155–165.
30. Høiby N, Bjarnsholt T, Givskov M, et al. Antibiotic resistance of bacterial biofilms. *Int J Antimicrob Agents*. 2010;35(4):322–332.
31. Marshall BM and Levy SB. Food animals and antimicrobials: Impacts on human health. *Clin Microbiol Rev*. 2011;24(4):718–733.
32. World Health Organization (WHO). Antimicrobial resistance: Global report on surveillance. Geneva, Switzerland: World Health Organization; 2014. [Online]. Available: <https://www.who.int/publications/i/item/9789241564748>. Accessed November 1, 2024.
33. Lambert T. Antibiotics that affect the ribosome. *Rev Sci Tech*. 2012;31(1):57–64.
34. You Y and Silbergeld EK. Learning from agriculture: Understanding low-dose antimicrobials as drivers of resistome expansion. *Front Microbiol*. 2014;5:284.
35. Wooldridge M. Evidence for the circulation of antimicrobial-resistant strains and genes in nature and especially between humans and animals. *Rev Sci Tech*. 2012;31(1):231–247.
36. Marti R, Scott A, Tien YC, et al. Impact of manure fertilization on the abundance of antibiotic-resistant bacteria and resistance genes in soil and on vegetables at harvest. *Appl Environ Microbiol*. 2013;79(18):5701–5709.
37. Woolhouse ME, Ward MJ. Sources of antimicrobial resistance. *Science*. 2013;341(6153):1460–1461.
38. Smith R, Coast J. The true cost of antimicrobial resistance. *BMJ*. 2013;346:f1493.
39. Tamma PD, Cosgrove SE. Antimicrobial stewardship. *Infect Dis Clin North Am*. 2011;25(1):245–260.
40. Littmann J, Viens AM. The ethical significance of antimicrobial resistance. *Public Health Ethics*. 2015;8(3):209–224.
41. Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. *Infect Control Hosp Epidemiol*. 2010;31(Suppl 1):S7–S10.
42. Hussein S, Qurbani K, Ahmed SK. Potential increase in Crimean-Congo hemorrhagic fever incidence in Iraq post Eid-al-Adha, 2023. *New Microbes New Infect*. 2023;54:101175.
43. Doyle ME. Multidrug-resistant pathogens in the food supply. *Foodborne Pathog Dis*. 2015;12(4):261–279.
44. World Bank. Drug-resistant infections: A threat to our economic future. Washington, DC: International Bank for Reconstruction and Development/The World Bank; 2017.
45. Arnold KE, Laing G, McMahon BJ, et al. The need for One Health systems-thinking approaches to understand multiscale dissemination of antimicrobial resistance. *Lancet Planet Health*. 2024;8(2):124–133.
46. Pokharel S, Raut S, Adhikari B. Tackling antimicrobial resistance in low-income and middle-income countries. *BMJ Glob Health*. 2019;4(6):e002104.

47. Hou J, Long X, Wang X, et al. Global trend of antimicrobial resistance in common bacterial pathogens in response to antibiotic consumption. *J Hazard Mater.* 2023;442:130042.
48. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. *Pathog Glob Health.* 2015;109(7):309–318.
49. Mancuso G, Midiri A, Gerace E, et al. The global spread of antimicrobial resistance: Implications for prevention and treatment. *Int J Antimicrob Agents.* 2021;57(2):106186.
50. Inoue H. Strategic approach for combating antimicrobial resistance. *Glob Health Med.* 2018;1(2):61–66.

Citation Pal M and Rebuma T. Antimicrobial resistance: A one health approach to addressing global health and food security challenges. *J Bio Med Open Access.* 2026;6(1):135.